中順潔柔(002511.SZ)業績快報:2022年度淨利同比下降39.43%
格隆匯2月27日丨中順潔柔(002511.SZ)披露2022年度業績快報,報吿期內,公司實現營業收入85.70億元,同比下降6.34%;實現歸屬於上市公司股東的淨利潤3.52億元,同比下降39.43%,業績變動的主要因素系:
1、國內部分地區受疫情管控影響,疊加產品提價策略及渠道結構調整,短期內銷售受到一定影響。公司積極開展應對措施,第四季度實現營業收入24.56億元,環比增長40.62%。
2、國際原材料、包材及能源價格上漲導致生產成本上升,疊加消費市場疲軟不振、市場競爭激烈等原因,毛利率同比有所下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.